BroadOak Capital Partners
VC Fund
Bethesda, United States
BroadOak Capital Partners is a VC fund in Bethesda focused on Biotechnology and Life Science. BroadOak Capital Partners, LLC is a privately held investment bank with a comprehensive focus on the life sciences industry. They offer advisory services including mergers and acquisitions, divestitures, business combinations, capital formation, valuations and fairness opinions. Their sector focus includes research tools and consumables,diagnostics, therapeutics, healthcare IT, pharmaceutical services and medical devices.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 64%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BroadOak Capital Partners invests in
Stages BroadOak Capital Partners invests in
Countries BroadOak Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill Snider
|
|||
|
Kyle Wilson
|
|||
Lars Hanan
|
|||
Timothy Johnson
|
|||
Timothy Johnson
|
Investment Focus
Industry
- Biotechnology 19 (53%)
- Life Science 9 (25%)
- Health Care 8 (22%)
- Medical 5 (14%)
- Genetics 5 (14%)
Stage
- Venture - Series Unknown 8 (22%)
- Series A 5 (14%)
- Series B 5 (14%)
- Funding Round 5 (14%)
- Series C 3 (8%)
Country
- United States 25 (69%)
- Israel 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bill Snider
Partner
|
Partner | Total investments: 8 | Find email | |
|
Kyle Wilson
Partner
|
Partner | Total investments: 0 | Find email | |
|
Lars Hanan
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 0 | Find email | |
|
Timothy Johnson
Partner
|
Partner | Total investments: 0 | Find email | |
|
Timothy Johnson
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Quartzy
|
Quartzy provides the only complete solution for lab management that includes the world’s most comprehensive catalog of more than 3M lab supplies and deals backed by 1,000's of top suppliers. Trusted by 200,000 scientists across 13,000 labs nationwide, Quartzy streamlines inventory and purchasing communications to save labs time and money. | $23M / Debt Financing / Apr 13, 2026 | |
Axol Bioscience
|
Axol specialize in human cell culture. Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers. These are iPSC-derived cells and the media and reagents required to successfully culture these cells. The company also do iPSC reprogramming and differentiation to various cell types as a service forcustomers that wish to use their own patient-derived samples.Axol is headquartered and maintains production on the Chesterford Research Park, a location renowned for inspiring innovation and success, located in Cambridge, UK. | $2.8M / Venture - Series Unknown / Jan 13, 2026 | |
Harvard Bioscience
|
Harvard Bioscience, Inc. is a global developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. The Company sells its products to thousands of researchers inover 100 countries through its 850 page catalog (and various other specialty catalogs), Website, through distributors, including GE Healthcare, Thermo Fisher Scientific Inc. and VWR, and via its field sales organization. The Company's product range is targeted towards two major application areas: ADMET testing and molecular biology and liquid handling. | $40M / Post-IPO Debt / Dec 17, 2025 | |
Azure Biosystems
|
Azure Biosystems are a team of highly experienced scientists, engineers, and entrepreneurs dedicated to accelerating their client's science. | Venture - Series Unknown / Nov 12, 2025 | |
Codis
|
Codis is a contract development and manufacturing organization (CDMO) specializing in commercial spray drying drying and particle engineering for enhanced bioavailability, high-performance materials, and pharmaceutical supply. | Private Equity / Oct 16, 2025 | |
Kromatid
|
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents.It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on DirectionalGenomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studiesCo-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007. | $8M / Series C / Aug 20, 2025 | |
S2 Genomics
|
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomicanalyses.S2 Genomics was founded in 2016 and is headquartered in Livermore, CA. | $16M / Series A / Jan 23, 2024 | |
Pluristyx
|
Pluristyx provides the expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics to treat serious human diseases by providing unique products, expert consulting, and contract services. | Venture - Series Unknown / Dec 21, 2023 | |
Telesis Bio
|
Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA. Telesis Bio was founded in 2013 and was headquartered in San Diego, USA. | $74.2M / Post-IPO Equity / May 31, 2023 | |
PBS Biotech
|
PBS Biotech offers single-use bioreactors and process development services for cell product manufacturing. Their single-use bioreactors have the smallest per liter volume footprints and are fully scalable for any stage of the cell culture process, from R&D to clinical to cGMP production. They provide efficient, cost-effective disposable systemsand top-notch technical services to help their customers solve complex cell culture challenges. | $22M / Venture - Series Unknown / Jan 09, 2023 | |
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BroadOak Capital Partners invest in?
BroadOak Capital Partners invests primarily in Biotechnology, Life Science and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BroadOak Capital Partners?
Public channels for BroadOak Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BroadOak Capital Partners?
The team at BroadOak Capital Partners includes Bill Snider (Partner), Kyle Wilson (Partner) and Lars Hanan (Co-Founder & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
